Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …
patients who could benefit from these treatments becomes critical. In this study, we …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Role of aducanumab in the treatment of Alzheimer's disease: Challenges and opportunities
M Vaz, V Silva, C Monteiro… - Clinical interventions in …, 2022 - Taylor & Francis
Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …